Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 4, Pages 574-581
Publisher
Wiley
Online
2015-11-06
DOI
10.1002/cncr.29778
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
- (2015) J. S. Chen et al. ANNALS OF ONCOLOGY
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
- (2014) A F Hezel et al. BRITISH JOURNAL OF CANCER
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
- (2013) I. Borbath et al. ANNALS OF ONCOLOGY
- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
- (2013) D. P. S. Sohal et al. ANNALS OF ONCOLOGY
- Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases
- (2013) Francesco Leone et al. CANCER
- Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study
- (2013) G. Rubovszky et al. EUROPEAN JOURNAL OF CANCER
- Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
- (2012) L. H. Jensen et al. ANNALS OF ONCOLOGY
- Biliary tract carcinomas: From chemotherapy to targeted therapy
- (2012) Donatella Marino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prognostic Factors in Patients With Gallbladder Cancer After Surgical Resection
- (2012) Hyun Lim et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
- (2010) Atul Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma
- (2008) S.A. Khan et al. HPB
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search